|
JPS55164687A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164685A
(en)
*
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
HU230586B1
(hu)
|
1999-06-25 |
2017-02-28 |
Genentech, Inc. |
Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
|
|
EP2289549A3
(de)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
EP1392359B2
(de)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Spezifische bindungsproteine und ihre verwendung
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
WO2005010044A2
(en)
|
2003-07-08 |
2005-02-03 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
ES2431929T3
(es)
|
2001-09-18 |
2013-11-28 |
Genentech, Inc. |
Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
AU2004239301B2
(en)
|
2003-05-09 |
2010-08-19 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
NZ542695A
(en)
|
2003-05-20 |
2009-04-30 |
Immunogen Inc |
Improved cytotoxic agents comprising new maytansinoids
|
|
EP2457587A1
(de)
|
2003-06-27 |
2012-05-30 |
Amgen Fremont Inc. |
Auf die Deletionsmutanten des epidermalen Wachstumsfaktorrezeptors gerichtete Antikörper und ihre Verwendungen
|
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
|
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
|
DK1718677T3
(da)
|
2003-12-19 |
2012-07-09 |
Genentech Inc |
Monovalente antistoffragmenter egnede som terapeutiske midler
|
|
EP1753463A2
(de)
*
|
2004-06-01 |
2007-02-21 |
Genentech, Inc. |
Antikörper-wirkstoff-konjugate und verfahren
|
|
CN101044164A
(zh)
|
2004-07-20 |
2007-09-26 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂，组合，以及其用途
|
|
NZ551908A
(en)
|
2004-07-26 |
2009-10-30 |
Genentech Inc |
Methods and compositions for modulating hepatocyte growth factor HGF activation
|
|
US20060045877A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
KR101364276B1
(ko)
*
|
2004-09-03 |
2014-02-20 |
제넨테크, 인크. |
인간화 항-베타７ 길항제 및 그의 용도
|
|
EP1841793B1
(de)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
WO2007094842A2
(en)
*
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
EP1995321A2
(de)
|
2005-08-15 |
2008-11-26 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
NZ621483A
(en)
|
2005-12-02 |
2015-10-30 |
Genentech Inc |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
EP1973948B1
(de)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
|
CN103360496B
(zh)
|
2006-01-05 |
2015-11-18 |
健泰科生物技术公司 |
抗ephb4抗体及其使用方法
|
|
CA2638133A1
(en)
|
2006-01-20 |
2007-11-08 |
Genentech, Inc. |
Anti-ephrinb2 antibodies and methods using same
|
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
EP2007428A2
(de)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
|
|
AU2007297565A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
|
JP2010503407A
(ja)
|
2006-09-12 |
2010-02-04 |
ジェネンテック・インコーポレーテッド |
癌の診断及び治療のための方法及び組成物
|
|
DK2845866T3
(en)
|
2006-10-27 |
2017-07-10 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
ES2609094T3
(es)
*
|
2007-01-25 |
2017-04-18 |
Dana-Farber Cancer Institute, Inc. |
Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
|
|
CN101652389A
(zh)
|
2007-02-09 |
2010-02-17 |
健泰科生物技术公司 |
抗robo4抗体及其用途
|
|
JP5618549B2
(ja)
*
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
SI2176296T1
(sl)
|
2007-07-16 |
2012-05-31 |
Genentech Inc |
Protitelesa proti CD b in imunokonjugati in postopki za uporabo
|
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
|
ES2395784T3
(es)
*
|
2007-11-12 |
2013-02-15 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnosis de la influenza
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
BRPI0821447A2
(pt)
*
|
2007-12-26 |
2015-06-16 |
Biotest Ag |
Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
|
|
JP2011507933A
(ja)
*
|
2007-12-26 |
2011-03-10 |
バイオテスト・アクチエンゲゼルシヤフト |
免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
|
|
MX2010007102A
(es)
*
|
2007-12-26 |
2011-07-01 |
Biotest Ag |
Inmunoconjugados dirigidos contra cd138 y sus usos.
|
|
PL2240516T3
(pl)
*
|
2007-12-26 |
2015-12-31 |
Biotest Ag |
Sposoby i środki do ulepszania nakierowania na komórki nowotworowe z ekspresją CD138
|
|
US8133488B2
(en)
|
2008-01-18 |
2012-03-13 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
CA2718878A1
(en)
*
|
2008-03-10 |
2009-09-17 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
|
AU2009225877B2
(en)
|
2008-03-18 |
2014-11-20 |
Genentech, Inc. |
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
AU2009233708B2
(en)
|
2008-04-09 |
2015-06-04 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
KR101361905B1
(ko)
*
|
2008-05-16 |
2014-02-21 |
제넨테크, 인크. |
베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
|
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
|
PE20120080A1
(es)
|
2008-10-01 |
2012-02-17 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
|
MX2011006516A
(es)
|
2008-12-17 |
2011-08-04 |
Genentech Inc |
Terapia de combinacion de virus de hepatitis c.
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
AU2010226453B2
(en)
|
2009-03-20 |
2013-11-21 |
Genentech, Inc. |
Bispecific anti-HER antibodies
|
|
BRPI1006448B1
(pt)
|
2009-03-25 |
2021-08-17 |
Genentech, Inc |
Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
|
|
MX2011010264A
(es)
|
2009-04-01 |
2011-10-11 |
Genentech Inc |
Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
|
|
EP2414391B1
(de)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispezifische antikörper, umfassend vollständige antikörper und einzelketten-fab-fragmente
|
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ， インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
ES2513292T3
(es)
|
2009-07-31 |
2014-10-24 |
Genentech, Inc. |
Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
|
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
UY32913A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
|
|
US8759491B2
(en)
*
|
2009-10-19 |
2014-06-24 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
|
MX2012004647A
(es)
|
2009-10-22 |
2012-06-19 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso.
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
CA2780143A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
|
CN102741294A
(zh)
|
2009-11-30 |
2012-10-17 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
JP5818805B2
(ja)
|
2009-12-11 |
2015-11-18 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ−ｃ抗体及びその使用方法
|
|
NZ600826A
(en)
|
2009-12-23 |
2014-09-26 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
|
EP2538981B1
(de)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
BR112012027001A2
(pt)
|
2010-04-23 |
2016-07-19 |
Genentech Inc |
produção de proteínas heteromultiméricas
|
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック， インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
CA3109036C
(en)
|
2010-08-31 |
2023-08-01 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
AU2011299066A1
(en)
|
2010-09-10 |
2013-03-21 |
Apexigen, Inc. |
Anti-IL-1 beta antibodies and methods of use
|
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
MX2013009357A
(es)
|
2011-02-14 |
2014-02-17 |
Theraclone Sciences Inc |
Composiciones y metodos para la terapia y diagnostico de la influenza.
|
|
MX342810B
(es)
|
2011-03-03 |
2016-10-13 |
Apexigen Inc |
Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
|
|
KR20140012131A
(ko)
|
2011-03-15 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
|
US8778345B2
(en)
|
2011-04-29 |
2014-07-15 |
Apexigen, Inc. |
Anti-CD40 antibodies
|
|
US20140161827A1
(en)
|
2011-05-09 |
2014-06-12 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
US20140105915A1
(en)
|
2011-05-27 |
2014-04-17 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - binding proteins
|
|
JP2014525412A
(ja)
|
2011-08-17 |
2014-09-29 |
ジェネンテック， インコーポレイテッド |
難治性腫瘍における血管新生の阻害
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
CA2849318C
(en)
|
2011-09-22 |
2019-11-12 |
Amgen Inc. |
Cd27l antigen binding proteins
|
|
EP2776051A4
(de)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
Therapeutische kombinationen und verfahren zur behandlung von melanomen
|
|
CA2854153A1
(en)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
EP2780040A1
(de)
|
2011-11-16 |
2014-09-24 |
Amgen Inc. |
Verfahren zur behandlung von durch den epidermalen wachstumsfaktorlöschungsmutanten viii bedingten erkrankungen
|
|
KR20140100571A
(ko)
|
2011-12-08 |
2014-08-14 |
바이오테스트 아게 |
Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
|
|
EP2794653B1
(de)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック， インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
TW201402609A
(zh)
|
2012-05-01 |
2014-01-16 |
Genentech Inc |
抗ｐｍｅｌ１７抗體及免疫結合物
|
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
CN108586487B
(zh)
|
2012-09-26 |
2021-11-05 |
伊缪诺金公司 |
用于美登醇酰化的改进的方法
|
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
EP2948478B1
(de)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antikörper gegen cdh19 für melanome
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
BR112015022019A2
(pt)
|
2013-03-14 |
2017-08-29 |
Genentech Inc |
Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
NZ753995A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
|
EP3013365B1
(de)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2-antigene und verwendung davon
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
|
PL3027208T3
(pl)
|
2013-07-31 |
2020-11-02 |
BioNTech SE |
Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
|
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
|
EA201600252A1
(ru)
|
2013-09-12 |
2017-05-31 |
Галозим, Инк. |
Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
|
|
HK1218124A1
(zh)
|
2013-09-17 |
2017-02-03 |
豪夫迈．罗氏有限公司 |
使用抗lgr5抗体的方法
|
|
EP3054987B1
(de)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem-8-antikörper und deren verwendung
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
PE20160712A1
(es)
|
2013-12-13 |
2016-07-26 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
|
EA201691023A1
(ru)
|
2013-12-16 |
2016-10-31 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
|
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック， インコーポレイテッド |
抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
|
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
|
EP3129767B1
(de)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reaktive markierungsverbindungen und ihre verwendungen
|
|
HK1232127A1
(zh)
|
2014-04-11 |
2018-01-05 |
Medimmune, Llc |
双特异性her2抗体
|
|
EP3140392B1
(de)
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Herstellung von heteromultimeren proteinen mittels säugerzellen
|
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
|
CA2950577A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
EP4116329A1
(de)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2-glykoantikörper und verwendungen davon
|
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
|
JP7286267B2
(ja)
|
2014-08-28 |
2023-06-05 |
バイオアトラ インコーポレイテッド |
修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
|
|
EP3191500A4
(de)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
|
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
HUE052460T2
(hu)
|
2014-09-12 |
2021-04-28 |
Genentech Inc |
Anti-HER2 antitestek és immunkonjugátumok
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
EP3689910A3
(de)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von anti-cd79b-immunkonjugaten
|
|
WO2016054315A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
|
KR102691114B1
(ko)
|
2015-01-24 |
2024-08-01 |
아카데미아 시니카 |
신규한 글리칸 콘주게이트 및 이를 사용하는 방법
|
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
CN116063543A
(zh)
|
2015-04-24 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US11078286B2
(en)
|
2015-09-20 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
|
|
US10421810B2
(en)
|
2015-10-09 |
2019-09-24 |
Lentigen Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
CA3011734A1
(en)
|
2016-01-27 |
2017-08-03 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス，インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
GEAP202214922A
(en)
|
2016-04-15 |
2022-02-10 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
KR102697688B1
(ko)
|
2016-04-15 |
2024-08-21 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
PT3455261T
(pt)
|
2016-05-13 |
2022-11-11 |
Bioatla Llc |
Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações
|
|
EP3465221B1
(de)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
EP3500594A4
(de)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
Antikörper, bindungsfragmente und verfahren zur verwendung
|
|
CA3035615A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
|
EP4219556A3
(de)
|
2016-12-21 |
2023-10-11 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Menschliche antikörper spezifisch für flt3 und deren verwendungen
|
|
WO2018129524A1
(en)
|
2017-01-09 |
2018-07-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3601356A1
(de)
|
2017-03-24 |
2020-02-05 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd33-immuntherapie
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
EP3625256A1
(de)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
|
AU2018337671B2
(en)
|
2017-09-19 |
2021-03-04 |
Paul Scherrer Institut |
Transglutaminase conjugation method and linker
|
|
ES2958849T3
(es)
|
2017-10-16 |
2024-02-15 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia anti-CD22
|
|
CA3079215A1
(en)
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd117+ cells
|
|
CN117756946A
(zh)
|
2017-11-03 |
2024-03-26 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
IL316155A
(en)
|
2017-11-29 |
2024-12-01 |
Heidelberg Pharma Res |
Compositions and Methods for the Depletion of CD5(PLUS) CELLS
|
|
AU2018388997B2
(en)
|
2017-12-20 |
2025-04-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
|
AU2019301675B2
(en)
|
2018-07-12 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
AU2019311077B2
(en)
|
2018-07-23 |
2025-05-29 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
CA3106544A1
(en)
|
2018-08-08 |
2020-02-13 |
Mitchell Ho |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
EP3853254A1
(de)
|
2018-09-20 |
2021-07-28 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd123-immuntherapie
|
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
|
EP3886895A1
(de)
|
2018-11-30 |
2021-10-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd38-immuntherapie
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
CA3125033A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
AU2020232789A1
(en)
|
2019-03-06 |
2021-10-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
KR20220144753A
(ko)
|
2019-03-19 |
2022-10-27 |
폴 슈레 앙스띠뛰 |
글리신 기반 링커를 사용한 트랜스글루타미나제 컨쥬게이션 방법
|
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
|
EP3976653A1
(de)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-bcma-immuntherapie
|
|
US20220380474A1
(en)
|
2019-07-02 |
2022-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Monoclonal antibodies that bind egfrviii and their use
|
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
|
AU2020365836A1
(en)
|
2019-10-18 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
|
|
AU2020370125A1
(en)
|
2019-10-22 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
|
|
JP7679380B2
(ja)
|
2019-12-12 |
2025-05-19 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
|
|
MX2022013198A
(es)
|
2020-04-24 |
2022-11-14 |
Genentech Inc |
Metodos de uso de inmunoconjugados anti-cd79b.
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
|
JP2023542910A
(ja)
|
2020-09-18 |
2023-10-12 |
アラリス バイオテック アーゲー |
アミノ酸に基づくリンカーを使用したトランスグルタミナーゼコンジュゲーション方法
|
|
MX2023004606A
(es)
|
2020-10-25 |
2023-05-08 |
Araris Biotech Ag |
Medios y metodos para producir conjugados de ligador-anticuerpo.
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
JP2023548555A
(ja)
|
2020-11-05 |
2023-11-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
AU2022273063A1
(en)
|
2021-05-12 |
2023-11-23 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CA3220227A1
(en)
|
2021-05-28 |
2022-12-01 |
Matthew Bruce |
Combination therapies for treating cancer
|
|
WO2022261017A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
EP4422695A1
(de)
|
2021-10-25 |
2024-09-04 |
Araris Biotech AG |
Verfahren zur herstellung von antikörper-linker-konjugaten
|
|
KR20240150807A
(ko)
|
2022-02-22 |
2024-10-16 |
아라리스 바이오테크 아게 |
2개 이상의 페이로드를 포함하는 펩티드 링커
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
JP2025526420A
(ja)
|
2022-07-28 |
2025-08-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
固形腫瘍を処置するためのキメラ抗原受容体治療
|
|
AU2023329412A1
(en)
|
2022-08-26 |
2025-03-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
AU2024296940A1
(en)
|
2023-07-07 |
2026-01-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2026006682A1
(en)
|
2024-06-27 |
2026-01-02 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells
|
|
US20260014265A1
(en)
|
2024-07-10 |
2026-01-15 |
Araris Biotech Ag |
TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs)
|